Last reviewed 2026-04-20 · How we verify

Vaspit (FLUOCORTIN BUTYL)

Phase 2 active Small molecule

Vaspit (generic name: FLUOCORTIN BUTYL) is a fluocortin butyl drug. It is currently in Phase 2 development.

Vaspit works by binding to glucocorticoid receptors in the body, mimicking the effects of cortisol.

Vaspit, also known as fluocortin butyl, is a small molecule drug of the corticosteroid class. Its exact target and mechanism of action are unknown, but it is believed to work by mimicking the effects of cortisol in the body. Vaspit is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to determine its safety and efficacy. As a result, key safety considerations and potential side effects are currently unclear.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLUOCORTIN BUTYL
Drug class	fluocortin butyl
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Vaspit is the key, and the glucocorticoid receptor is the lock. When Vaspit binds to the receptor, it triggers a response that helps to reduce inflammation and suppress the immune system.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vaspit CI brief — competitive landscape report
Vaspit updates RSS · CI watch RSS

Frequently asked questions about Vaspit

What is Vaspit?

Vaspit (FLUOCORTIN BUTYL) is a fluocortin butyl drug.

How does Vaspit work?

Vaspit works by binding to glucocorticoid receptors in the body, mimicking the effects of cortisol.

What is the generic name of Vaspit?

FLUOCORTIN BUTYL is the generic (nonproprietary) name of Vaspit.

What drug class is Vaspit in?

Vaspit belongs to the fluocortin butyl class. See all fluocortin butyl drugs at /class/fluocortin-butyl.

What development phase is Vaspit in?

Vaspit is in Phase 2.

Drug class: All fluocortin butyl drugs
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing